National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is offering two Funding Opportunity Announcements (FOAs) soliciting R01 and R21 applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.
Posted Date: April 4, 2018
Open Date (Earliest Submission Date): July 7, 2018
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Date(s): August 7, 2018; December 4, 2018; April 2, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
No late applications will be accepted for this Funding Opportunity Announcement.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
For more information:
Filed Under: Funding Opportunities